Implementation of disease and safety predictors during disease management in UC
|
|
- Walter West
- 5 years ago
- Views:
Transcription
1 Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM
2 Case presentation A 52 year old male patient, Ashkenazi origin was diagnosed with UC A non-smoker, with only occasional alcohol consumption The patient`s father had CRC (diagnosed at 61 years of age), no history of IBD in family He has had to stop his work for the last 3 weeks due to a high number of stools and tenesmus
3 Prognosis items Gender The patient is a male Poor outcome Colectomy rates higher for men vs women, both for early colectomy ( < 90 days from diagnosis date) (males vs females: 2.6% vs 1.1%; HR = 2.37, 95%; CI = ; P = ) and for late colectomy (> 90 days from diagnosis) (males vs females: HR=1.28, , P= 0.036) Targownik LE et al. The epidemiology of colectomy in UC: results from a population-based cohort. Am J Gastroenterol 2012
4 AGE He is 52 years old at diagnosis Not prognostic Older age at diagnosis of UC ( 60y <) Increases the risk of CRC (P=0.033), may also reduce the risk a shorter disease duration ( SIR=8.6;95% CI= ) Reduces the risk of disease extension Reduces the risk of acute-severe colitis and colectomy ( p=0.0003, HR=0.28;95% CI= ) Shi HY et al. Natural history of elderly-onset UC. JCC 2016; Jess T et al. Risk of CRC in patients with UC. Clin Gastroenterol Hepatol 2012; Charpenter C et al. Natural history of elderly-onset IBD. GUT 2014; Solberg IC et al. Clinical course during the first 10 years of UC. Scand J Gastroenterol 2009.
5 LIFESTYLE He is an ex-smoker and an occasional drinker Poor outcome Active smoking in UC has been associated with a lower risk of: Hospitalization (p=0.01) Flares (HR=0.8;95% CI= ) Colectomy (OR=0.57;95% CI= ) Insufficient evidence that alcohol consumption has a definite prognostic value in UC Odes HS et al. Effects of cigarette smoking on clinical course of CD and UC. Dig Dis Sci 2001; Hoie O et al. UC: patient chracteristics may predict 10-year disease recurrence. Am J Gastroenterol 2007.
6 Family history The patient`s father had CRC Poor outcome CRC in a first-degree relative increases the risk of CRC The prognosis of CRC is poorer for patients with UC than for patients without UC A family history of IBD can help predict UC diagnosis, but no definite prognostic value in UC Askling J et al. Gastroenterology 2001; Jensen AB et al. Survival after CRC in patients with UC. Am J Gastroenterol 2006.
7 CASE PRESENTATION- CONT The patient has experienced back pain for the last 2-3 years with morning stiffness He was prescribed NSAID`S > 1 year ago by his primary physician, were effective against the pain, were stopped due to a severe allergic reaction At consultation, his joints are not swollen, and there is no limitation in movement of the axial or peripheral joints There are no skin lesions present. No EIM was diagnosed
8 EIM manifestations No EIM was diagnosed Favorable outcome EIM in pediatric UC populations higher risk of colectomy (HR=3.5; ) and UC-related surgery In adult UC patients higher risk of UC-related surgery (p< 0.001, OR = ;95% CI= ) As EIMs were not diagnosed at presentation, a favorable outcome is likely Whilst not prognostic, ongoing NSAID`S use is associated with an increased risk of flares in UC In this case, the patient stopped taking NSAID`S more than 1 year ago Safroneeva E et al. Prevalence and risk factors for therapy escalation in UC. Inflamm Bowel Dis 2015; Kvasnovsky CL et al. NSAID`S ese and excacerbations of IBD. Scand J Gastroenterol 2015.
9 Clinical examination 7-8 stools /day ( of which ~ 50% are bloody) Tenesmus- debilitating for employment Mild abdominal pain No fever Pulse rate = 17 beats/min Blood pressure = 135/85 mmhg No evidence of acute-severe colitis Partial Mayo Score of 5 was calculated (5/9) Not prognostic No predictors of outcome were found on examination
10 Laboratory tests HB 12.8 g/dl WBC cells/mm3 CRP 1.4 mg/l (normal < 5) Albumin 4.2 mg/dl Fecal Calprotectin was not measured Favorable outcome Travis SP et al. Predicting outcome in severe UC. GUT 2008.; Kumar S et al. Severe UC: prospective study of parameters determining outcome. J Gastroenterol Hepatol 2004.
11 Endoscopy Active inflammation up to 45 cm Complete loss of vascular pattern, moderate friability with bleeding upon contact Small erosions, but no large or deep ulcers A series of inflammatory pseudopolyps in sigmoid Normal mucosa beyond 45 cm upon cecum UC endoscopic index of severity (UCEIS) = 6 Endoscopic Mayo score = 2 Favorable outcome No sign of severe colitis (deep ulcers, mucosal abrasion etc.) or extensive disease Presence of multiple pseudopolyps an increased risk of CRC Beaugerie L et al. Clinical, serological and genetic predictors of IBD course. World J Gastroenterol 2012; Velayos FS et al. Predictive and protective factors associated with CRC in UC. Gastroenterol 2006.
12 UCEIS: Evolving endoscopic scoring in UC
13 MAYO UC endoscopic scoring
14 Initial treatment The patient was initially treated with 5-ASA ( 4 gr orally and 1 gr suppositories) Favorable outcome Use of steroids upon diagnosis associated with proximal disease extension in adults with ulcerative proctitis An absence of response to first-line treatment with mesalazine and a need for early steroid therapy increased risk of disease extension Kim B et al. Proximal disese extension and related predicting factors in UC. Scand J Gastroenterol 2014; Waterman M et al. Predictors of outcome in UC. Inflamm Bowel Dis 2015.
15 Age > 60 y Prognostic factors for benign disease course Lack of EIM diagnosis on presentation No extensive colitis Presentation with mild/moderate flare only (reflected by initial laboratory tests and endoscopy)
16 Young age Prognostic factors for poor outcome Presence of pseudopolyps risk for CRC (if inflammation is not controlled) Absence of response to primary therapy of 5-ASA increased risk for disease extension and colectomy
17 Case presentation - Cont No significant improvement was observed with oral and rectal mesalazine Severe tenesmus,10 bloody stool movements a day Low grade fever and abdominal tenderness PO steroid therapy was initiated No response Severe weakness and worsening of rectal bleeding Hospitalization and administration of IV steroids
18 What are bad prognostic factors for acute severe colitis? 1. Concomitant PSC 2. Extensive disease 3. Active smoking 4. Family history of IBD 5. Disease duration > 10 y
19 Prognostic factors for acute severe UC Extensive disease Younger age at diagnosis Shorter duration of disease Concurrent infection-cmv/cdt clinical risk factors PSC Active smoking Protective prognostic factors
20 Potential UC disease course over first 10 y
21 Natural history of UC
22 Features of progressive disease in UC
23 Laboratory tests HB 9 g/dl bad outcome WBC cells/mm3 CRP 25 mg/l (normal < 5) Albumin 2.1 mg/dl Fecal Calprotectin Increased CRP at diagnosis Increased risk of colectomy (p = 0.02, OR= 4.8;95% CI= ) Increased CRP Increased risk of refractoriness to medical therapy, particularly in acute severe colitis Severe anemia (< 10 g/dl)- A sign of acute-severe colitis in association with other factors Low albumin levels- A marker of severe colitis and a predictor of refractoriness to medical therapy (p = 0.026) Travis SP et al. Predicting outcome in severe UC. GUT 2008.; Kumar S et al. Severe UC: prospective study of parameters determining outcome. J Gastroenterol Hepatol 2004.
24 Severe and refractory colitis on endoscopy
25 Case presentation - cont Steroid pulse therapy without response CT- diffuse sigmoid and des. Colon thickening Repeat Sigmoidoscopy showing very severe UC, CMV neg Still had bloody BM/day, 2-3 BM/night, weight loss of 7 kg over 10 days Mantoux test inconclusive under steroids Anti- TNF therapy was initiated
26 Which anti-tnf to choose? Infliximab? Adalimumab?
27 ADA and IFX were similarly effective in the treatment of moderate to severe UC in the real world clinical setting
28 Yet, in acute severe colitis: IFX is recommended!
29 Acute severe colitis (ASUC) The most aggressive presentation of UC Occurs in 15% of patients Refractoriness to iv steroids in 50% of adults and 33% of children Similar rates of response to calcineurin inhibitors and IFX More favorable adverse effect profile of anti-tnf 30% of adults with ASUC colectomy within 60 days, 20% of children within a year
30
31 Higher serum concentrations of anti-tnf biologics = better outcome
32 ASUC- accelerated clearance of anti-tnf
33 Alternative dosing regimens may be needed in patients with ASUC
34 Which of the factors is most associated with rapid anti-tnf clearance? 1. Elevated CRP 2. Weight under 40 kg 3. High levels of fecal calprotectin 4. Low albumin 5. Positive panca
35 Factors associated with drug PK and/or clinical outcomes after anti TNF therapy for UC Baseline factors Age Sex Race Weight Albumin Association with PK IFX clearance rates faster in men Directly associated with IFX volume of distribution Directly associated with serum IFX levels in children Low albumin associated with low serum IFX concentrations rapid clearance Association with outcomes Inversely associated with clinical response to IFX Increased rates of response of GLM in females White race associated with higher rates of GLM clinical response Inversely associated with frequency of IFX dose escalation in children Low albumin associated with lower IFX response rates, increased colectomy rates and increased frequency of IFX dose escalation in children
36 Baseline factor CRP ESR Fecal inflammatory markers Association with PK Inversely associated with IFX levels Association with outcomes Inversely associated with GLM response High ESR increased frequency of IFX dose escalation in children Fecal lactoferrin inversely associated with GLM response Fecal calpro inversely related to IFX response in ASUC Mayo score panca TNF Inversely associated with IFX levels Inversely associated with incidence of clinical remission Associated with decreased rates of clinical response to IFX Mucosal TNF gene expression inversely associated with response to IFX
37 Case presentation - cont Slight improvement. Still 7 bloody diarrhea a day, CRP 18 High dose of anti TNF (10 mg/kg) was administered a week after
38 Over the course of the next 1-2 weeks, slow improvement After 3 rd induction dose of IFX- complete remission Follow up colonoscopy- complete mucosal healing, some pseudopolyps Continues on Infliximab and 5-ASA
39 In summary Acute severe colitis is an emergency setting in IBD It is characterized with higher clearance rates of anti TNF However, optimal time points and targets for early anti-tnf levels are unknown Proactive strategy with frequent and higher dosages of anti-tnf with monitoring of drug level is highly recommended
40 The future development and clinical application of PK modeling will likely result in Sustained exposure to the drug Mucosal healing Fewer colectomies in children and adults with ASUC
41 THANK YOU!
Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationIBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital
IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital Aims To understand the aetiology of IBD To understand the impact that
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationNON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente
NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND Fabrizio Parente Gastrointestinal Unit, A.Manzoni Hospital, Lecco & L.Sacco School of Medicine,University of Milan - Italy
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More information-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency
SD, male 40 yrs. old. (680718M467.) -2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine -June 2008: Recurrence of rectal blood loss and urgency Total colonoscopy: ulcerative rectitis,
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationTreatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG
Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationAchieving Success in Ulcerative Colitis: the Role of Infliximab
Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationHow to differentiate Segmental Colitis Associated with Diverticulosis and Inflammatory Bowel Diseases?
How to differentiate Segmental Colitis Associated with Diverticulosis and Inflammatory Bowel Diseases? Alessandro Armuzzi Lead IBD Unit Complesso Integrato Columbus Fondazione Policlinico Gemelli Università
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationInflammatory Bowel Disease: Clinical updates. Dr Jeff Chao Princess Alexandra Hospital
Inflammatory Bowel Disease: Clinical updates Dr Jeff Chao Princess Alexandra Hospital Inflammatory bowel disease 2017 Clinical updates and future directions Pathogenesis Treatment targets Therapeutic agents
More informationOp#mizing)Management)in)IBD:) Mucosal)Healing)
Op#mizing)Management)in)IBD:) Mucosal)Healing) Vipul&Jairath&MD&PhD& Associate&Professor&of&Medicine,&Epidemiology&and& Biosta=s=cs& Western&University&&& Division&of&Gastroenterology,&& London&Health&Sciences&Network&
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationSURGICAL MANAGEMENT OF ULCERATIVE COLITIS
SURGICAL MANAGEMENT OF ULCERATIVE COLITIS Cary B. Aarons, MD Associate Professor of Surgery Division of Colon & Rectal Surgery University of Pennsylvania AGENDA Background Diagnosis/Work-up Medical Management
More informationUlcerative colitis (UC) is a. The Patient with Newly Diagnosed Ulcerative Colitis: Anticipating the Questions and Individualizing the Answers
The Patient with Newly Diagnosed Ulcerative Colitis: Anticipating the Questions and Individualizing the Answers James Gregor, MD, Division of Gastroenterology, The University of Western Ontario, London,
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationClinical Study Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis
Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2013, Article ID 192794, 6 pages http://dx.doi.org/10.1155/2013/192794 Clinical Study Clinical Study of the Relation between
More informationCan We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA
Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA Endpoints Overview Hospitalization Surgery Colorectal cancer
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More informationAgenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
More informationMichael D. Kreines, M.D.
Michael D. Kreines, M.D. Gastroenterology Section Chief Medical Director, IBD Program The Christ Hospital of Cincinnati Ohio GI and Liver Institute www.ohiogi.com This Year s Story How to figure out how
More informationTitle: Author: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationSpectrum of Diverticular Disease. Outline
Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives
More informationIBD advanced course 2nd meeting IGA Meeting Hilton TLV
IBD advanced course 2nd meeting IGA Meeting Hilton TLV 6.1.2017 https://www.ibdvia.com Age Sanjeet is 24 years of age at diagnosis 1:Non- Predictors 2:Favorable prognosis 3:Poor prognosis Age- as a Prognostic
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationManagement of the Hospitalized IBD Patient. Drew DuPont MD
Management of the Hospitalized IBD Patient Drew DuPont MD Ulcerative Colitis: Indications for Admission Severe ulcerative colitis Frequent loose bloody stools ( 6 per day) Severe cramps Systemic toxicity:
More informationEvaluation of treatment effect in UC and CD (children)
Evaluation of treatment effect in UC and CD (children) Dr Nick Croft Digestive Diseases, Centre for Immunobiology, Blizard Institute & Barts Health NHS Trust Blizard Institute Disclosures Dr Nick Croft
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationNEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL
NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL CROHN S DISEASE Chronic disease of uncertain etiology Etiology- genetic, environmental, and infectious Transmural
More informationAlgorithm for managing severe ulcerative colitis
Tropical Gastroenterology 2014;Suppl:S40 44 Algorithm for managing severe ulcerative colitis Vineet Ahuja 1, Ajay Kumar 2, Rakesh Kochhar 3 ABSTRACT Dept of Gastroenterology, 1 All India Institute of Medical
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationIl ruolo degli anticorpi anti farmaco nella pratica clinica
Il ruolo degli anticorpi anti farmaco nella pratica clinica Daniela Pugliese, MD IBD Unit Complesso Integrato Columbus Gemelli Hospital Catholic University Foundation, Rome - Italy Therapeutic Drug monitoring
More informationINFLAMMATORY BOWEL DISEASE
National University Faculty of Medicine INFLAMMATORY BOWEL DISEASE Gehan M. Osman, MD. MBBS Pediatrician Jaffar Ibn Auf Specialized Hospital EDUCATIONAL OBJECTIVES Definitions and spectrum of (IBD) Epidemiology
More informationDiagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases
Diagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases Parakkal Deepak, M.B.B.S., M.S. Assistant Professor of Medicine Division of Gastroenterology John T. Milliken Department
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationAvailable Data on Pediatric Exposure Response a Clinician s Perspective
Available Data on Pediatric Exposure Response a Clinician s Perspective Marla Dubinsky, MD Professor of Pediatrics and Medicine Chief Pediatric GI and Nutrition Co-Director Susan and Leonard Feinstein
More informationOptimizing Therapies for Severe Ulcerative Colitis October 19, 2014
Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014 Ellen J. Scherl, MD, FACP, FACG, AGAF, FASGE, NYSGEF Director Jill Roberts Center for Inflammatory Bowel Disease Jill Roberts IBD Research
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationManagement of Moderate to Severe Ulcerative Colitis
Management of Moderate to Severe Ulcerative Colitis Neilanjan Nandi, MD Assistant Professor of Medicine Associate Program Director Division of Gastroenterology Drexel University College of Medicine Hahnemann
More informationPrimary & Secondary Care Inflammatory Bowel Disease Pathway February 2018
South East London Area Prescribing Committee: Primary & Secondary Care Inflammatory Bowel Disease Pathway February 2018 Developed by: South East London IBD Pathway Development Group Approved: February
More informationOptimizing Management using CRP, Fecal Calprotectin and Ferritin. Peter Laszlo Lakatos 1st Department of Medicine Semmelweis University Budapest
Optimizing Management using CRP, Fecal Calprotectin and Ferritin Peter Laszlo Lakatos 1st Department of Medicine Semmelweis University Budapest Objectives Overview of disease progression Old and new treatment
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationCLINICAL INSIGHTS 01
P2 Borrowing a Treatment Paradigm From Rheumatoid Arthritis P4 Antidrug Antibody Monitoring in Practice P6 Proactive Drug Monitoring Informs Therapeutic Dose Adjustments P7 Keeping Patients in Remission
More informationCancer Risk with IBD Therapies How to Discuss with your Patients?
Cancer Risk with IBD Therapies How to Discuss with your Patients? Douglas L Nguyen, MD Assistant Clinical Professor of Medicine University of California, Irvine Medical Center H.H. Chao Comprehensive Digestive
More informationProctitis Workshop. PD Dr Michel H. Maillard, MD-PhD 1,2. Crohn s and Colitis Center, Gastroentérologie Beaulieu SA.
Proctitis Workshop PD Dr Michel H. Maillard, MD-PhD 1,2 1 Crohn s and Colitis Center, Gastroentérologie Beaulieu SA 2 CHUV, Lausanne PD Dr Lukas Brügger, Universitätsklinik für Viszerale Chirurgie und
More informationCASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD
CASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD Disclosure Statement NKC: No relevant conflicts to disclose. DTR: No relevant
More informationWhat s new in IBD? Dr AB Hawthorne Consultant Gastroenterologist University Hospital of Wales Cardiff
What s new in IBD? Dr AB Hawthorne Consultant Gastroenterologist University Hospital of Wales Cardiff Case: Kelly age 19 Admitted via medical intake to local hospital with D&V for 10 days. Ate take-away
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationMild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France
Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested Philippe Marteau, Paris, France Sequential vs combined treatments When should one switch? Sequential vs combined treatments
More informationPouchitis and Cuffitis A bloody mess. Sze-Lin Peng Colorectal Surgeon Counties Manukau District Health Board
Pouchitis and Cuffitis A bloody mess Sze-Lin Peng Colorectal Surgeon Counties Manukau District Health Board Ileal-pouch anal anastomosis https://www.pennmedicine.org/for-health-care-professionals/for-physicians/physician-education-and-resources/clinicalbriefings/2018/february/total-proctocolectomy-with-jpouch-reconstruction-for-ulcerative-colitis
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationABDOMINAL PAIN AND DIARRHEA - IT S NOT (ALWAYS) WHAT YOU THINK. Yakov Wainer, MD Gastroenterology and Hepatology Meir Medical Center
ABDOMINAL PAIN AND DIARRHEA - IT S NOT (ALWAYS) WHAT YOU THINK Yakov Wainer, MD Gastroenterology and Hepatology Meir Medical Center 1 ST ADMISSION - 2015 38 y/o female Abdominal pain, diarrhea - intermittent
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC
ULCERATIVE COLITIS Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC What is Ulcerative Colitis? Ulcerative colitis (UC) is a disease marked by inflammation
More informationDiarrhoea for the Acute Physician
Diarrhoea for the Acute Physician STEPHEN INNS GASTROENTEROLOGIST AND PHYSICIAN HUTT VALLEY DHB August 2013 Outline Case History 1 Initial assessment of acute diarrhoea Management of fulminant UC Management
More informationThe Spectrum of IBD. Inflammatory Bowel Disease. Symptoms. Epidemiology. Tests for IBD. CD or UC? Inflamatory Bowel Disease. Fernando Vega, M.D.
The Spectrum of IBD Inflammatory Bowel Disease Fernando Vega, M.D. Epidemiology CD and UC together 1:400 UC Prevalence 1:500 UC Incidence 6-12K/annum CD Prevalence 1:1000 CD Incidence 3-6K/annum Symptoms
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationThe future of IBD therapeutic research
The future of IBD therapeutic research Jean-Frederic Colombel, MD Director Susan and Leonard Feinstein IBD Clinical Center Icahn School of Medicine, Mount Sinai Hospital New York J-F Colombel has served
More informationDisease Monitoring. Symptoms Activity. No Symptoms No Activity. What is the Problem with Dogma? What are the FACTS
Heal the Mucosa or Heal the Patient (Data vs Dogma) Heal the Mucosa Cary G. Sauer MD MSCR Associate Professor, Emory University School of Medicine Clinical Director, IBD Program The Facts vs The Force
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant
More informationOutcomes of immunosuppressors and biologic drugs in inflammatory bowel diseases: a real life experience
Outcomes of immunosuppressors and biologic drugs in inflammatory bowel Treatments and therapeutic approaches in IBD are constantly evolving. The newly emerged biologic treatments are one such evolving
More informationTreatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
Alimentary Pharmacology and Therapeutics Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort N. Gies, K. I. Kroeker, K. Wong & R. N. Fedorak Division
More informationGionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico
Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways
More information2015 복영증례 51/M C.C. Past Hx: DM, HTN (1998), Lab: WBC (11500/ μl ), CRP (0.71 mg/dl) 순천향서울병원황지영, 홍성숙 APCT (HAD #1) APCT (HAD#1) APCT (HAD #15)
Case 1 2015 복영증례 순천향서울병원황지영, 홍성숙 51/M C.C Abdominal pain and chilling (1 week ago) Diarrhea (a month ago) Past Hx: DM, HTN (1998), Alcoholic liver disease (2008) Lab: WBC (11500/ μl ), CRP (0.71 mg/dl)
More informationCurrent management options and recent advances in IBD
n DRUG REVIEW Current management options and recent advances in IBD Ben Warner BSc, MRCP and Peter Irving MA, MD, FRCP SPL The advent of biological therapies has revolutionised the management of inflammatory
More informationTherapeutic Drug Monitoring και ΙΦΝΕ το 2018
Therapeutic Drug Monitoring και ΙΦΝΕ το 2018 TDM: Ναι το χρειαζόμαστε, σε όλους και πάντοτε Κωνσταντίνος Κατσάνος Conflict of interest By means of this, the speaker confirms that he receives honoraria
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationA Case of Crohn s Disease with Mesalazine Allergy that was Difficult to Differentiate from Comorbid Ulcerative Colitis
doi: 10.2169/internalmedicine.1607-18 http://internmed.jp CASE REPORT A Case of Crohn s Disease with Mesalazine Allergy that was Difficult to Differentiate from Comorbid Ulcerative Colitis Rumiko Tsuboi,
More informationClinical Trials in IBD. Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases
Clinical Trials in IBD Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases Objectives Today s discussion will address the following topics: Similarities and differences between Crohn
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationIBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital
IBD Case Studies David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust
More informationLooking for Answers. IBD Research March 9, Dr. Benjamin Click, MD MS Associate Staff Cleveland Clinic
Looking for Answers IBD Research 2019 March 9, 2019 Dr. Benjamin Click, MD MS Associate Staff Cleveland Clinic Disclosures No relevant financial disclosures There is still no cure for IBD Why me? ETIOLOGY
More informationPredicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab
More informationINFLAMMATORY BOWEL DISEASE
1. Medical Condition INFLAMMATORY BOWEL DISEASE (IBD) specifically includes Crohn s disease (CD) and ulcerative colitis (UC) but also includes IBD unclassified (IBDu), seen in about 10% of cases. These
More informationHighlights of DDW 2015: Crohn s disease
Highlights of DDW 2015: Crohn s disease Mark S. Silverberg, MD, PhD, FRCPC Associate Professor of Medicine, University of Toronto Staff Gastroenterologist, Mount Sinai Hospital Senior Investigator, Lunenfeld-Tanenbaum
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationTREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS
TREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS Target Audience: Physicians, Physician Assistants, Nurse Practitioners and Nurses impacted by the protocol. Scope/Patient Population: All adult
More information